These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 2107534

  • 1. Nursing implications in the administration of ifosfamide and mesna.
    Richters JE.
    Oncol Nurs Forum; 1990; 17(2):276. PubMed ID: 2107534
    [No Abstract] [Full Text] [Related]

  • 2. Ifosfamide and mesna.
    Med Lett Drugs Ther; 1989 Nov 03; 31(804):98-9. PubMed ID: 2554100
    [No Abstract] [Full Text] [Related]

  • 3. Oral administration of mesna with ifosfamide.
    Goren MP.
    Semin Oncol; 1996 Jun 03; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [Abstract] [Full Text] [Related]

  • 4. Ifosfamide and Mesna in advanced malignancies.
    Li GC, Brock N, Li JQ, Guan ZZ, He YJ.
    Chin Med J (Engl); 1988 Mar 03; 101(3):213-20. PubMed ID: 3136996
    [No Abstract] [Full Text] [Related]

  • 5. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Semin Oncol; 1996 Jun 03; 23(3 Suppl 6):97-8. PubMed ID: 8677458
    [Abstract] [Full Text] [Related]

  • 6. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Czownicki Z, Utracka-Hutka B.
    Nowotwory; 1981 Jun 03; 30(4):377-83. PubMed ID: 6792599
    [No Abstract] [Full Text] [Related]

  • 7. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
    Sakurai M, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Sano T, Suemasu K, Jett JR.
    Jpn J Clin Oncol; 1986 Jun 03; 16(2):153-6. PubMed ID: 3090314
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
    Scheulen ME, Niederle N, Bremer K, Schütte J, Seeber S.
    Cancer Treat Rev; 1983 Sep 03; 10 Suppl A():93-101. PubMed ID: 6414700
    [Abstract] [Full Text] [Related]

  • 9. Ifosfamide and mesna.
    Schoenike SE, Dana WJ.
    Clin Pharm; 1990 Mar 03; 9(3):179-91. PubMed ID: 2107997
    [Abstract] [Full Text] [Related]

  • 10. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL, Sandlund JT, Miser JS, Arasi V, Linehan M, Magrath IT.
    J Clin Oncol; 1987 May 03; 5(5):799-803. PubMed ID: 3106585
    [Abstract] [Full Text] [Related]

  • 11. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Marti C, Steiner R, Viollier AF.
    Schweiz Med Wochenschr; 1979 Dec 08; 109(47):1885-7. PubMed ID: 119317
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
    Ingle JN, Krook JE, Mailliard JA, Hartmann LC, Wieand HS.
    Am J Clin Oncol; 1995 Dec 08; 18(6):498-501. PubMed ID: 8526193
    [Abstract] [Full Text] [Related]

  • 13. [Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
    Matsumoto S, Kawaguchi N, Manabe J, Kuroda H, Shimoji T.
    Gan To Kagaku Ryoho; 1995 Jun 08; 22(7):965-8. PubMed ID: 7794006
    [No Abstract] [Full Text] [Related]

  • 14. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Iwasaku-Fujimoto M, Fujiwara F, Todo S, Morioka Y, Imashuku S.
    Gan To Kagaku Ryoho; 1990 Mar 08; 17(3 Pt 1):403-6. PubMed ID: 2106836
    [Abstract] [Full Text] [Related]

  • 15. Clinical overview of mesna.
    Burkert H.
    Cancer Treat Rev; 1983 Sep 08; 10 Suppl A():175-81. PubMed ID: 6414692
    [Abstract] [Full Text] [Related]

  • 16. Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
    Pratt CB, Douglass EC, Etcubanas E, Goren MP, Green AA, Hayes FA, Horowitz ME, Meyer WH, Thompson EI, Wilimas JA.
    Semin Oncol; 1989 Feb 08; 16(1 Suppl 3):51-5. PubMed ID: 2495567
    [Abstract] [Full Text] [Related]

  • 17. Mesna: continuous or bolus infusion?
    Willemse PH, de Vries EG.
    J Clin Oncol; 1989 Jun 08; 7(6):817-9. PubMed ID: 2497231
    [No Abstract] [Full Text] [Related]

  • 18. Fatal hypokalaemia associated with ifosfamide/mesna chemotherapy.
    Husband DJ, Watkin SW.
    Lancet; 1988 May 14; 1(8594):1116. PubMed ID: 2896952
    [No Abstract] [Full Text] [Related]

  • 19. Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma.
    De Forges A, Droz JP, Ghosn M, Theodore C.
    Cancer Treat Rep; 1987 Nov 14; 71(11):1103. PubMed ID: 3119203
    [No Abstract] [Full Text] [Related]

  • 20. Encephalopathy with rapid infusion ifosfamide/mesna.
    Perren TJ, Turner RC, Smith IE.
    Lancet; 1987 Feb 14; 1(8529):390-1. PubMed ID: 2880199
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.